HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$70.95

Market cap

$8.42B

P/E Ratio

23.97

Dividend/share

N/A

EPS

$2.96

Enterprise value

$10.25B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 55
Relative Valuation: Rel. Valuation: 41
Relative Profitability: Rel. Profitability: 91

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
The company's revenue rose by 39% YoY and by 8% QoQ
HALO's gross profit is up by 38% YoY and by 7% QoQ
HALO's net income is down by 28% year-on-year but it is up by 10% since the previous quarter
HALO's EPS is down by 23% year-on-year but it is up by 12% since the previous quarter
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 35% from the previous quarter
The company's equity has shrunk by 54% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
1.62%
1 week
4.06%
1 month
9.88%
1 year
31.75%
YTD
5.42%
QTD
9.78%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.25B
Operating income
$511.99M
Net income
$348.84M
Gross margin
82.8%
Net margin
23.1%
The net margin has contracted by 48% YoY
The company's revenue rose by 39% YoY and by 8% QoQ
HALO's gross profit is up by 38% YoY and by 7% QoQ
The operating margin has declined by 38% year-on-year

Price vs fundamentals

How does HALO's price correlate with its fundamentals

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
23.97
P/B
38.12
P/S
5.56
EV/EBIT
19.61
EV/EBITDA
16.43
EV/Sales
6.79
The stock's price to earnings (P/E) is 28% more than its last 4 quarters average of 18.5 and 19% more than its 5-year quarterly average of 19.8
HALO's EPS is down by 23% year-on-year but it is up by 12% since the previous quarter
The company's equity has shrunk by 54% YoY
HALO's price to book (P/B) is 36% lower than its last 4 quarters average of 58.3 and 2.5% lower than its 5-year quarterly average of 38.5
The company's revenue rose by 39% YoY and by 8% QoQ
The price to sales (P/S) is 36% lower than the 5-year quarterly average of 8.5 and 6% lower than the last 4 quarters average of 5.8

Efficiency

How efficient is Halozyme Therapeutics business performance
HALO's return on sales is down by 40% year-on-year
Halozyme Therapeutics's return on assets has decreased by 37% YoY but it has increased by 4.3% QoQ
The ROE has grown by 36% from the previous quarter and by 3.4% YoY
HALO's return on invested capital is down by 14% year-on-year but it is up by 7% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 9% higher than its total liabilities
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 35% from the previous quarter
The company's current ratio has shrunk by 67% YoY and by 41% QoQ
Halozyme Therapeutics's debt to equity has plunged by 78% from the previous quarter
The company's equity has shrunk by 54% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.